Assembly Biosciences expands ABI-6250 trials to cholestatic liver diseases

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. HOOD
10. IBM

Go back to Assembly Biosciences expands ABI-6250 trials to cholestatic liver diseases
(NASDAQ: ASMB) Delayed: 25.15 +0.71 (2.91%)
Previous Close $24.44    52 Week High $14.50 
Open $24.50    52 Week Low $4.33 
Day High $26.14    P/E N/A 
Day Low $24.44    EPS $0.00 
Volume 286,842